The U.S. Trade Representative launched a Section 301 investigation into Germany’s drug pricing policies, arguing the U.S. shoulders a disproportionate share of global biopharma R&D costs. USTR ambassador Jamieson Greer said the probe follows Germany’s fast-tracking of legislation intended to save more than €16 billion in healthcare spending and reduce insurer burdens.